REGN 17092
Alternative Names: REGN-17092Latest Information Update: 27 Dec 2023
At a glance
- Originator Regeneron Pharmaceuticals
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 28 Nov 2023 Phase-I clinical trials in COVID-2019 infections (In Volunteers) in Belgium (IV) (NCT05923424) (EudraCT2023- 505041-52-00)
- 28 Nov 2023 Phase-I clinical trials in COVID-2019 infections (In Volunteers) in Belgium (SC) (NCT05923424) (EudraCT2023- 505041-52-00)
- 28 Jun 2023 Regeneron Pharmaceuticals plans a phase I trial for COVID-2019 infections (In volunteers) in August 2023 (NCT05923424)